0001628280-26-032620
SEC filingStrong operational quarter with double-digit revenue growth and a return to profitability, driven by volume and pricing gains across all regions.
Revenue for the first quarter of 2026 increased 17.5% to $116.3 million compared to $99.0 million in the prior year period. The growth was driven by higher unit volumes and increased average selling prices across North America, EMEA, and APAC, reflecting gains in market share. The increase in volume of higher-priced tissues shipped also contributed to the revenue performance.
Net income for the quarter was $1.4 million, or $0.03 per diluted share, compared to a net loss of $0.5 million, or $(0.01) per diluted share, in the prior year. The return to profitability was driven by revenue growth and margin expansion.
The company continues to focus on market share gains across all regions. Based on experience with similar agreements, management believes that acquired procurement contracts and agreements have indefinite useful lives, as they expect to continue renewing these contracts for the foreseeable future.